麻豆原创

Leading Therapeutic Companies in Field of RNA-Targeted Small Molecules

• Accent Therapeutics
• Anima Biotech Inc.
• Arrakis Pharmaceuticals
• Epics Therapeutics
• Expansion Therapeutics
• Gotham Therapeutics
• H3 Biomedicine
• Ribometrix
• Skyhawk Therapeutics
• STORM Therapeutics
• Twentyeight-Seven Therapeutics

听

The RNA-Targeted Small Molecules 麻豆原创 report describes and analyzes from an industry perspective with a view on emerging technology companies regarding their founding background, financial history, technological capabilities, target and indication selection, and most advanced lead compounds.

This report is very useful for decision-makers, venture capital, private equity and investment managers in Big Pharma companies, R&D Portfolio, Technology, and Strategy Management and clinical specialists.

ORDER THIS REPORT

• mRNA translation regulation;
• RNA splicing modification
• Direct RNA targeting; and
• Epitranscriptomics, i.e. indirectly targeting RNA via the proteins it is interacting with.

Recent Investment in RNA-Targeted Small Molecules Therapeutics

• In September 2019, Ribometrix has announced USD 7.8 million in additional funding from existing investors, the Dementia Discovery Fund and Illumina Ventures. The new funding will strengthen the ongoing development of the Ribometrix discovery platform, which uses sophisticated structural analysis and proprietary assays to identify ligands that bind to highly structured pockets in therapeutically compelling RNAs to modulate protein expression.
• In May 2019, STORM Therapeutics announced that it has raised an additional 拢14 million bringing the total Series A financing to 拢30 million (USD 38.43 million). The funding will enable STORM to advance its current pipeline further in preclinical development and accelerate its programmes towards the clinic, supporting STORM's growth as the leading drug discovery company working on RNA modulating enzymes.
• On April 2019, Arrakis Therapeutics announced USD 75 million Series B financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
• In December 2018, EPICS Therapeutics SA announced that it will raise Euro 14.2 million (USD 16.1 million) to fund its discovery and development of innovative small molecules anti-cancer drugs.
• In October 2018, Gotham Therapeutics was formed with a USD 54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One. Gotham Therapeutics will be developing a novel drug class targeting RNA-modifying proteins.
• In July 2018, Anima Biotech entered an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. Under the terms of the agreement, Anima will receive USD 30 million in upfront payments and USD 14 million in research funding.
• In May 2018, Accent Therapeutics announced USD 40 million in Series A capital to establish a discovery platform and pipeline of therapeutic candidates targeting RMPs.
• On January 2018 Expansion Therapeutics, Inc. closed of a USD 55.3 million Series A funding co-led by 5AM Ventures, Kleiner Perkins, Novartis Venture Fund, and Sanofi Ventures with participation from RA Capital Management and Alexandria Venture Investments. The funding will strengthen the Expansion鈥檚 portfolio of small molecule drugs targeting key human disease-driving RNAs.听